Anti-HIV effects of HIV vectors.
We have recently developed an HIV-1 packaging cell line, psi 422, as an improved tool for anti-HIV gene therapy. After stable transfection with an HIV-1 or HIV-2 vector, psi 422 has been shown to synthesize virions able to transduce CD4+ T cells and macrophages. We now report that HIV vectors per se, in the absence of antiviral genes, inhibit HIV infection of transduced cells. This antiviral effect was shown to be due, at least in part, to a TAR and RRE decoy effect. These data highlight further advantages of HIV-derived gene delivery systems for HIV therapy, in addition to CD4 cell targeting and the ability to transduce nondividing cells.
Corbeau
P
P
Department of Medicine and Biology, University of California, San Diego 92093-0665, USA.
Wong-Staal
F
F
D019380:Anti-HIV Agents; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002472:Cell Transformation, Viral; D015694:Gene Products, rev / Q000037:antagonists & inhibitors; D015696:Gene Products, tat / Q000037:antagonists & inhibitors; D005822:Genetic Vectors; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000235:genetics*; D015498:HIV-2 / Q000235:genetics*; D006367:HeLa Cells; D006801:Humans; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus
D019380:Anti-HIV Agents; D015694:Gene Products, rev; D015696:Gene Products, tat; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus